Finnhub · May 6, 2026
CytoMed Therapeutics : Audited Financial Statements for FY2025
CYTOMED THERAPEUTICS LIMITED AND ITS SUBSIDIARIES Directors' Statement and Financial Statements for the financial year ended 31 December 2025 ...
GD
NASDAQ · GDTC
CytoMed Therapeutics Limited
Healthcare · Biotechnology
$0.89
Down-$0.05 (-5.81%)
Updated Oct 10, 2026, 3:12 AM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 19.36M
- P/E ratio
- -5.82
- Dividend yield
- 0.00%
- 52-week range
- $0.68 – $1.39
- Volume
- 11.82K
- Avg. volume
- 120.59K
Price performance · GDTC
GDTC price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
GDTC closed at $0.89 after 21 trading sessions, up 13.84% for the selected period.
- Last close
- $0.89
- Period change
- +13.84%
- Period low
- $0.78
- Period high
- $1.01
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $0.9385 | $0.94 | $0.853 | $0.89 | 11.82K |
| Oct 8, 2026 | $0.90 | $0.945 | $0.90 | $0.9449 | 23.22K |
| Oct 7, 2026 | $0.90 | $0.98 | $0.80 | $0.98 | 15.18K |
| Oct 6, 2026 | $0.95 | $0.95 | $0.8647 | $0.9298 | 18.56K |
| Oct 5, 2026 | $0.8453 | $1.06 | $0.8453 | $1.01 | 68.33K |
| Oct 2, 2026 | $0.80 | $0.92 | $0.7701 | $0.92 | 33.74K |
| Oct 1, 2026 | $0.843 | $0.90 | $0.838 | $0.8999 | 6.44K |
| Sep 30, 2026 | $0.8155 | $0.8498 | $0.7701 | $0.843 | 13K |
| Sep 29, 2026 | $0.8505 | $0.8914 | $0.81 | $0.889 | 30.71K |
| Sep 28, 2026 | $0.8988 | $0.93 | $0.8492 | $0.925 | 8.48K |
| Sep 25, 2026 | $0.9097 | $0.955 | $0.88 | $0.955 | 11.83K |
| Sep 24, 2026 | $0.91 | $0.91 | $0.8563 | $0.91 | 5.43K |
| Sep 23, 2026 | $0.8756 | $0.91 | $0.8737 | $0.91 | 9.68K |
| Sep 22, 2026 | $0.95 | $0.95 | $0.87 | $0.91 | 32.47K |
| Sep 21, 2026 | $0.97 | $0.97 | $0.8123 | $0.97 | 33.42K |
| Sep 18, 2026 | $0.82 | $0.98 | $0.7659 | $0.98 | 21.27K |
| Sep 17, 2026 | $0.8417 | $0.886 | $0.795 | $0.886 | 7.41K |
| Sep 16, 2026 | $0.8631 | $0.886 | $0.8064 | $0.886 | 4.28K |
| Sep 15, 2026 | $0.8516 | $0.852 | $0.80 | $0.8053 | 20.1K |
| Sep 14, 2026 | $0.77 | $0.90 | $0.77 | $0.8517 | 12.47K |
| Sep 11, 2026 | $0.8382 | $0.8382 | $0.7736 | $0.7818 | 10.01K |
Latest GDTC news
The latest Smart Investors Daily articles mentioning GDTC.
Stock researchCompany · Overview
Company
Market Activity
Research & News
GDTC research
Overview
Company profile and research snapshot.
Company profile
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 10, 2024 | Benchmark | Speculative Buy | — |
| Jun 11, 2024 | Benchmark | Speculative Buy | — |
| Dec 4, 2023 | Benchmark | Speculative Buy | — |
| Jul 21, 2023 | Benchmark | Speculative Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Jan 28, 2026
CytoMed Therapeutics Refutes Recent Statements Regarding Inaccurate, Misleading Claims About Company's Research Programs, Clinical Progress, And Operations
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable
Yahoo · Jan 13, 2026
CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital
SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to update shareholders as we enter a new exciting year in 2026. As mentioned in previous announcements,
defenseworld.net · Dec 12, 2025
CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 7.2% – Here’s Why
CytoMed Therapeutics Limited (NASDAQ: GDTC - Get Free Report)'s stock price was up 7.2% on Thursday. The stock traded as high as $1.67 and last traded at $1.67. Approximately 32,493 shares traded hands during mid-day trading, a decline of 59% from the average daily volume of 78,542 shares. The stock had previously closed at $1.5573.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
